Irbesartan Aurobindo

Irbesartan, the active ingredient in Irbesartan Aurobindo, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension, diabetic nephropathy and heart failure in adult patients. GNH USA supplies Irbesartan Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable global distribution to qualified healthcare providers.

Irbesartan belongs to the angiotensin II receptor blocker class and is used to treat conditions related to the renin‑angiotensin system.

Hypertension: reduces systolic and diastolic blood pressure by blocking AT1 receptors, improving vascular tone. Diabetic nephropathy: slows progression of renal impairment in patients with type 2 diabetes by decreasing intraglomerular pressure. Heart failure: lowers afterload and improves cardiac output, aiding symptom control in chronic heart failure.

Irbesartan is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Nasal congestion - Diarrhea or abdominal discomfort - Back pain

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Hyperkalemia (elevated blood potassium) - Acute renal failure or worsening kidney function - Severe hypotension - Hepatic injury (elevated liver enzymes) - Anaphylactic reactions

Before initiating Irbesartan, clinicians should consider several safety measures.

Monitor blood pressure: ensure adequate control without excessive hypotension. Assess renal function: check serum creatinine and eGFR at baseline and periodically. Check serum potassium: avoid hyperkalemia, especially with concomitant potassium‑sparing agents. Use caution in hepatic impairment: dose adjustment may be required. Avoid in patients with known hypersensitivity to Irbesartan or other ARBs. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors: additive effect on potassium and renal function. - Lithium: may raise lithium serum levels. - NSAIDs (high‑dose or chronic use): potential renal impairment.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, monitor blood pressure. - CYP2C9 inhibitors (e.g., fluconazole): may increase Irbesartan plasma concentrations. - Other antihypertensives: additive blood pressure lowering, adjust dose as needed.